HJM-561, a potent, selective and orally bioavailable EGFR PROTAC that overcomes osimertinib-resistant EGFR triple mutations.

已取消 20 由 Luke 发布于 2025/12/31 11:07:30

DOI:10.1158/1535-7163.MCT-21-0835
作者：Yong Du,?Yongfeng Chen,?Yuxia Wang,?Jinju Chen,?Xiaorong Lu,?Li Zhang,?Yan Li,?Zhaofu Wang,?Guozhong Ye,?George Zhang
文献类型：期刊论文
补充材料：只需要正文

American Association for Cancer Research (AACR)

Abstract：The epidermal growth factor receptor (EGFR) C797S mutation is the most common on-target resistance mechanism to osimertinib in patients with advanced non-small-cell lung cancer (NSCLC). Curr

应助信息

2025-12-31

Book学术机器人

2025/12/31 11:07:31 未找到该文献，机器人已退出，请等待人工下载

2025/12/31 11:07:30 Book学术AI机器人收到请求，开始寻找文献

2025/12/31 11:07:30 已向机器人发送请求

2025-12-31

Luke 发布求助

上一个求助:其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary 下一个求助:ElsevierBilayer-coating of MnO and N-doped carbon on SiO2 microspheres as a high-performance anode for flexible li-ion batteries